Patient-Choice Trial Boosts Arthritis Treatment Satisfaction
A multicenter randomized trial found rheumatoid arthritis patients who chose their own treatment reported greater satisfaction and fewer adverse events.
Updated on Nov. 3, 2026 in Arthritis
A multicenter randomized trial published online October 27 in RMD Open compared patient-chosen treatment with random assignment among 102 biologic disease-modifying antirheumatic drug-naive rheumatoid arthritis patients. Treatment satisfaction was significantly higher at 24 weeks in the patient-choice group.
Why it matters
The findings suggest that letting patients select between a subcutaneous TNF inhibitor and the oral JAK inhibitor filgotinib may improve treatment retention and reduce adverse events. The results add evidence to the growing focus on shared decision-making in managing chronic inflammatory conditions.
The trial enrolled 102 biologic disease-modifying antirheumatic drug-naive patients, with 55 percent of the patient-choice group selecting the oral JAK inhibitor and 45 percent selecting subcutaneous TNFi. Disease Activity Score differences at week 24 were numerically lower in the patient-choice group but were not statistically significant.
The players
RMD Open
RMD Open is a peer-reviewed open-access journal published by BMJ that covers rheumatic and musculoskeletal diseases.
The details
Patients were either allowed to choose between the two treatment options or were randomly assigned to them. Fewer patients in the patient-choice group switched to a different mode of action by week 12, and the randomized group used more glucocorticoids at that point.
Timeline
October 27, 2026: Study published online in RMD Open.
Week 12: Fewer patient-choice participants switched treatment modes than randomized participants.
Week 24: Treatment satisfaction measured significantly higher in the patient-choice group.
Health Landscape
The trial extends shared decision-making principles from rheumatology guidelines into a direct randomized comparison of patient choice versus random assignment among biologic-naive rheumatoid arthritis patients. It adds experimental evidence to a field where treatment selection has increasingly involved both injectable biologics and newer oral JAK inhibitors.
Patients with rheumatoid arthritis who are weighing injectable versus oral treatment options may find that involvement in the choice itself is associated with higher satisfaction and fewer switches. The trial found fewer adverse events in the patient-choice group, though it did not show a statistically significant difference in disease activity at 24 weeks.
The takeaway
Involving patients directly in choosing between biologic and oral rheumatoid arthritis treatments may improve satisfaction and reduce unwanted adverse events, even when disease activity outcomes are similar. Patients discussing options with their rheumatologists can ask how shared decision-making could fit their own care.
Further reading
For more on treatment options for joint inflammation, see Arthritis.
